JP2022542886A5 - - Google Patents
Info
- Publication number
- JP2022542886A5 JP2022542886A5 JP2022504582A JP2022504582A JP2022542886A5 JP 2022542886 A5 JP2022542886 A5 JP 2022542886A5 JP 2022504582 A JP2022504582 A JP 2022504582A JP 2022504582 A JP2022504582 A JP 2022504582A JP 2022542886 A5 JP2022542886 A5 JP 2022542886A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- optionally
- tumor
- masking agent
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878574P | 2019-07-25 | 2019-07-25 | |
| US62/878,574 | 2019-07-25 | ||
| PCT/US2020/070308 WO2021016640A1 (en) | 2019-07-25 | 2020-07-24 | Compositions and methods comprising protease-activated therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542886A JP2022542886A (ja) | 2022-10-07 |
| JP2022542886A5 true JP2022542886A5 (https=) | 2023-08-02 |
| JP7682150B2 JP7682150B2 (ja) | 2025-05-23 |
Family
ID=74194303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504582A Active JP7682150B2 (ja) | 2019-07-25 | 2020-07-24 | プロテアーゼ活性化治療剤を含む組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220281936A1 (https=) |
| EP (1) | EP4003401A4 (https=) |
| JP (1) | JP7682150B2 (https=) |
| CN (1) | CN114466657B (https=) |
| BR (1) | BR112022001320A2 (https=) |
| CA (1) | CA3148621A1 (https=) |
| MX (1) | MX2022000991A (https=) |
| WO (1) | WO2021016640A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7626577B2 (ja) | 2016-11-28 | 2025-02-07 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| US20240228586A1 (en) * | 2021-05-07 | 2024-07-11 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
| CN117957258A (zh) | 2021-07-19 | 2024-04-30 | 中外制药株式会社 | 利用融合多肽的蛋白酶介导的靶向特异性细胞因子递送 |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CN118647629A (zh) * | 2021-09-28 | 2024-09-13 | 苏州格治生物科技有限公司 | 含有TNF-α的免疫缀合物及其相关方法和组合物 |
| KR102609822B1 (ko) * | 2021-10-05 | 2023-12-06 | (주)케어젠 | 항염증 활성을 갖는 펩타이드와 이의 용도 |
| CA3234552A1 (en) | 2021-10-20 | 2023-04-27 | Synthekine, Inc. | Heterodimeric fc cytokines and uses thereof |
| CN113995855A (zh) * | 2021-11-10 | 2022-02-01 | 中国药科大学 | 一种抗纤维化纳米载体和纳米制剂及其制备方法 |
| CN114272390B (zh) * | 2021-12-29 | 2022-09-02 | 中山大学附属第一医院 | 一种微环境靶向联合细胞靶向肿瘤抑制载体及其制备方法和应用 |
| CN120112547A (zh) | 2022-11-16 | 2025-06-06 | 瑞泽恩制药公司 | 包含膜结合il-12和蛋白酶可裂解接头的嵌合蛋白 |
| CN119060196A (zh) * | 2023-05-31 | 2024-12-03 | 郑州大学 | 一种金属蛋白酶激活型car-t结构的制备及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0638644A1 (en) * | 1993-07-19 | 1995-02-15 | F. Hoffmann-La Roche Ag | Receptors of interleukin-12 and antibodies |
| US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| EP3263581B2 (en) | 2005-05-17 | 2025-07-09 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
| WO2007112051A2 (en) * | 2006-03-24 | 2007-10-04 | The Board Of Trustees Of The University Of Illinois | Polypyrimidine-tract binding protein (ptb) as a biomarker and target for the diagnosis and treatment of cancer |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| SG192673A1 (en) | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
| WO2016023040A1 (en) * | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| JP6933659B2 (ja) | 2016-03-18 | 2021-09-08 | ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ | トリプルネガティブ乳癌の治療方法 |
| BR112019005964A2 (pt) * | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| WO2018184003A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon |
| EP3634465A4 (en) * | 2017-05-25 | 2021-01-20 | The Broad Institute, Inc. | LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF |
| JP2020528878A (ja) | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| CN110396133B (zh) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| US20210221864A1 (en) * | 2018-08-24 | 2021-07-22 | City Of Hope | Masked cytokine conjugates |
| US20240228586A1 (en) * | 2021-05-07 | 2024-07-11 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
-
2020
- 2020-07-24 BR BR112022001320A patent/BR112022001320A2/pt unknown
- 2020-07-24 JP JP2022504582A patent/JP7682150B2/ja active Active
- 2020-07-24 WO PCT/US2020/070308 patent/WO2021016640A1/en not_active Ceased
- 2020-07-24 MX MX2022000991A patent/MX2022000991A/es unknown
- 2020-07-24 US US17/597,793 patent/US20220281936A1/en active Pending
- 2020-07-24 EP EP20844027.1A patent/EP4003401A4/en active Pending
- 2020-07-24 CA CA3148621A patent/CA3148621A1/en active Pending
- 2020-07-24 CN CN202080067433.2A patent/CN114466657B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542886A5 (https=) | ||
| JP2024517871A5 (https=) | ||
| CN113226472A (zh) | 双免疫细胞衔接物 | |
| US20200048331A1 (en) | Immunoregulatory structures from normally occuring proteins | |
| JP7848182B2 (ja) | 改善された抗原結合受容体 | |
| CA2289912A1 (en) | Human receptor proteins; related reagents and methods | |
| US20080299137A1 (en) | Fusion Proteins That Bind Effector Lymphocytes And Target Cells | |
| CA2386463A1 (en) | April receptor (bcma) and uses thereof | |
| US11352413B2 (en) | Engineered PD-1 variants | |
| WO2021092075A1 (en) | IL-2RβγC BINDING COMPOUNDS | |
| CN105744944B (zh) | 免疫系统调节器 | |
| JP2016525551A5 (https=) | ||
| ATE468127T1 (de) | Ii-key/antigene epitop-hybrid-peptid-vakzine | |
| Avery et al. | Characterization of factor H binding to human polymorphonuclear leukocytes. | |
| KR20220093323A (ko) | HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료 | |
| KR20240111753A (ko) | 개선된 항원 결합 수용체 | |
| CN119278052A (zh) | 预防或减轻与t细胞接合剂相关的不良反应 | |
| US20260103528A1 (en) | Nanobodies that bind to gprc5d and uses thereof | |
| KR101974583B1 (ko) | 링커 폴리펩티드 및 이를 이용한 표적 물질 분석 방법 | |
| JP2022535816A5 (https=) | ||
| Duk et al. | Identification of an epitope recognized by the monoclonal antibody PEP80 in the C-terminal cytoplasmic fragment of glycophorin A | |
| Harvey et al. | Cancer Cells Release a Covalent Complex Containing Disulfide-Linked Domains from Urinary Plasminogen Activator, Neural Cell Adhesion Molecule, and Haptoglobin α and β Chains | |
| KR20250051388A (ko) | 포밀메티오닌 항체 제작을 위한 항원 펩타이드 | |
| EA051364B1 (ru) | Улучшенные антигенсвязывающие рецепторы | |
| HK40056620A (en) | Twin immune cell engager |